Это пост из рекомендованной группы
AMD Gene Therapy: One-Time Genetic Interventions for Retinal Preservation
Gene therapy for Age-Related Macular Degeneration (AMD) aims to provide a one-time treatment for a condition that traditionally requires frequent, invasive injections. By delivering specific genes directly to the retinal cells, this therapy turns the eye into a "bio-factory" that produces proteins to prevent the progression of vision loss.
For "wet" AMD, the goal is to introduce genes that produce anti-VEGF proteins, which stop the growth of abnormal, leaking blood vessels. For "dry" AMD (specifically geographic atrophy), researchers are targeting the complement system, delivering genes that regulate the overactive immune response responsible for the destruction of light-sensing cells in the macula.
The delivery mechanism typically involves an adeno-associated virus (AAV) vector, which is injected into the subretinal space. This vector acts as a vehicle, carrying the therapeutic DNA into the retinal cells without causing disease itself. Once the cells are "reprogrammed," they can continue to secrete the necessary proteins for…